HAIFA, Israel--(BUSINESS WIRE)--April 24, 2006--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that the Company has started an animal model study of its innovative stem cell therapy product known as PLX-1. PLX-1 is intended to offer a breakthrough solution to improved engraftment during bone marrow transplant procedures that use umbilical cord blood (UCB).
